Buscar
Resultados de la búsqueda
- Combined NGcGM3/VSSP and Nimotuzumab in advanced non-small cell lung cancer (NSCLC)
-
... preparation NGcGM3/VSSP and the monoclonal antibody nimotuzumab, in patients with advanced non-small cell lung cancer (NSCLC) ... to 24 months Group B (patients with + EGF-R expression) nimotuzumab AcM (intravenous) : 200 mg, the first 6 doses every 7 days, and the ...
Clinical Trials - CIM - 21/12/2020 - 11:38am
- Kit frío de Nimotuzumab para el inmunodiagnóstico de tumores solidos
-
... y seguridad del kit frío del anticuerpo monoclonal nimotuzumab marcado con 99mTc para el inmunodiagnóstico de tumores de cabeza y ... claves: Nimotuzumab, cabeza y cuello, pulmón, gliomas ...
Ensayos Clínicos - CIM - 21/12/2020 - 11:23am
- Nimotuzumab cold kit for the immunodiagnosis of solid tumors
-
... Efficacy and safety of cold kit of monoclonal antibody nimotuzumab labeled with 99mTc for the immunodiagnosis of head and neck tumors, ... Group I- MAb Nimotuzumab 3mg (Experimental). Immunoscintigraphy with the ...
Clinical Trials - CIM - 21/12/2020 - 11:23am
- Nimotuzumab inoperable esophageal epithelial tumors, Phase IV
-
... title: Nimotuzumab safety and effectiveness in inoperable esophageal tumors of ... Experimental group (Nimotuzumab): 200 mg intravenous infusion in induction and maintenance scheme ...
Clinical Trials - CIM - 23/07/2020 - 6:59pm
- Nimotuzumab en tumores inoperables de esófago epitelial-Fase IV
-
... Seguridad y efectividad del Nimotuzumab en tumores inoperables de esófago de origen epitelial. Fase IV ... Grupo experimental (Nimotuzumab). Infusión intravenosa de 200 mg del producto en esquema de ...
Ensayos Clínicos - CIM - 23/07/2020 - 6:39pm
- Nimotuzumab-pancreatic cancer-adults-Phase IV.
-
... Evaluation of the safety and effectiveness of CIMAher® (Nimotuzumab) in the treatment of patients with locally advanced adenocarcinoma ... Group I (experimental): 2 year treatment with Nimotuzumab 400 mg once a week (intravenous) until discontinuation criteria, in ...
Clinical Trials - CIM - 23/07/2020 - 5:14pm
- Nimotuzumab-cáncer de páncreas-adultos-Fase IV
-
... Evaluación de la seguridad y efectividad del CIMAher® (Nimotuzumab) en el tratamiento de pacientes con adenocarcinoma de páncreas ... claves: Nimotuzumab, cáncer de páncreas localmente avanzado, irresecable, ...
Ensayos Clínicos - CIM - 23/07/2020 - 4:50pm
- Study of the mechanism of action of Nimotuzumab in patients with head and neck tumors
-
... Use of monoclonal antibody Nimotuzumab and radio-chemotherapy in the treatment of patients with locally ... Experimental group: RadioChemotherapy + Anti-EGFR mAb Nimotuzumab at 200 mg intravenously. The Nimotuzumab will have an induction ...
Clinical Trials - CIM - 17/02/2017 - 4:24pm
- Estudio del mecanismo de acción del Nimotuzumab en pacientes con tumores de cabeza y cuello
-
... Uso del anticuerpo monoclonal Nimotuzumab y radio-quimioterapia en el tratamiento de pacientes con cáncer de ... claves: nimotuzumab, ADCC, CTL, células T reguladoras, cross-presentación, cáncer de ...
Ensayos Clínicos - CIM - 17/02/2017 - 4:24pm
- NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer
-
... Immunotherapy with NGcGM3/VSSP and nimotuzumab in metastatic triple negative breast cancer patients. Phase I/II ... months Group 2 (experimental): Oncospecific treatment + nimotuzumab with the first six weekly doses of 200 mg (intravenous), then one ...
Clinical Trials - CIM - 22/12/2016 - 11:39am